News articles about Teleflex (NYSE:TFX) have trended somewhat positive recently, according to Accern Sentiment. Accern rates the sentiment of press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Teleflex earned a news impact score of 0.15 on Accern’s scale. Accern also gave news stories about the medical technology company an impact score of 47.0323761354607 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the media headlines that may have impacted Accern Sentiment’s scoring:
- Edited Transcript of TFX earnings conference call or presentation 22-Feb-18 1:00pm GMT (finance.yahoo.com)
- Q1 2018 Earnings Estimate for Teleflex Incorporated Issued By William Blair (TFX) (americanbankingnews.com)
- Analysts’ Recommendations for Haemonetics and Peers in March 2018 (finance.yahoo.com)
- NeoTract Reports Data From Large Real-World Study Of UroLift System (markets.businessinsider.com)
- Teleflex Incorporated (TFX) Given Consensus Rating of “Hold” by Analysts (americanbankingnews.com)
Several research firms have recently commented on TFX. Leerink Swann reaffirmed a “buy” rating and issued a $321.00 price target (up from $307.00) on shares of Teleflex in a report on Tuesday, January 30th. ValuEngine lowered shares of Teleflex from a “buy” rating to a “hold” rating in a report on Friday, December 1st. Stephens reaffirmed a “buy” rating and issued a $300.00 price target on shares of Teleflex in a report on Thursday, January 18th. Finally, TheStreet lowered shares of Teleflex from an “a-” rating to a “c+” rating in a report on Monday, March 12th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and six have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $281.56.
Teleflex (NYSE:TFX) last posted its earnings results on Thursday, February 22nd. The medical technology company reported $2.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.40 by $0.04. The firm had revenue of $595.10 million during the quarter, compared to analyst estimates of $601.17 million. Teleflex had a net margin of 7.11% and a return on equity of 16.46%. Teleflex’s revenue was up 15.8% on a year-over-year basis. During the same period in the previous year, the business posted $2.13 EPS. equities research analysts predict that Teleflex will post 9.66 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Thursday, March 15th. Shareholders of record on Friday, March 2nd were given a dividend of $0.34 per share. The ex-dividend date of this dividend was Thursday, March 1st. This represents a $1.36 dividend on an annualized basis and a dividend yield of 0.52%. Teleflex’s dividend payout ratio (DPR) is 41.59%.
In other Teleflex news, Director George Babich, Jr. sold 2,500 shares of the business’s stock in a transaction dated Monday, March 12th. The shares were sold at an average price of $268.53, for a total transaction of $671,325.00. Following the sale, the director now directly owns 11,083 shares in the company, valued at approximately $2,976,117.99. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Stephen K. M.D. Klasko sold 200 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $248.96, for a total transaction of $49,792.00. Following the sale, the director now owns 8,080 shares in the company, valued at $2,011,596.80. The disclosure for this sale can be found here. Insiders have sold a total of 14,259 shares of company stock worth $3,760,536 over the last 90 days. 2.39% of the stock is owned by insiders.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by BBNS and is owned by of BBNS. If you are reading this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The correct version of this piece of content can be viewed at https://baseballnewssource.com/2018/03/22/teleflex-tfx-earning-somewhat-favorable-news-coverage-analysis-shows/1927083.html.
Teleflex Company Profile
Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.